161 results about "S syndrome" patented technology

The present invention relates to an electrical nerve stimulator configured to deliver an electrical signal to a user to entrain Mu-band neural oscillations and / or Beta-band neural oscillations. The electrical nerve stimulator may be used in the treatment of neurological conditions associated with desynchronization of neural oscillations, such as Tourette's syndrome. The electrical nerve stimulator may be wearable on a wrist of a user, and may be configured to deliver rhythmic stimulation at a frequency falling within the same frequency range of Mu-band or Beta-band neural oscillations. The invention provides a convenient means of treating conditions such as Tourette's syndrome without the need for specialist medical equipment or facilities. Also disclosed is a method of delivering an electrical signal to a user to entrain Mu-band neural oscillations and / or Beta-band neural oscillations.

The present invention relates to an electrical nerve stimulator configured to deliver an electrical signal to a user to entrain Mu-band neural oscillations and / or Beta-band neural oscillations. The electrical nerve stimulator may be used in the treatment of neurological conditions associated with desynchronization of neural oscillations, such as Tourette's syndrome. The electrical nerve stimulator may be wearable on a wrist of a user, and may be configured to deliver rhythmic stimulation at a frequency falling within the same frequency range of Mu-band or Beta-band neural oscillations. The invention provides a convenient means of treating conditions such as Tourette's syndrome without the need for specialist medical equipment or facilities. Also disclosed is a method of delivering an electrical signal to a user to entrain Mu-band neural oscillations and / or Beta-band neural oscillations.

The invention relates to the technical field of data analysis, and particularly discloses a Down's syndrome screening system based on multiple key indicators, which comprises the following steps: analyzing historical sample data including pregnant woman age, body weight, race background, pregnancy history record, serum PAPP-A concentration, free beta-hCG concentration, neck transparent layer thickness and the like; mining a chromosome abnormality risk distribution rule; standardizing detection data by adopting a principal component analysis method, grouping pregnant woman features by utilizing a clustering algorithm, and determining a feature offset coefficient; establishing a personalized index reference interval by combining factors such as fetal structure abnormality, chromosome abnormality and family genetic disease history; generating personalized risk probability distribution by fusing individual features and ultrasonic measurement data; according to the method, the risk value is calculated and the dynamically adjusted risk prediction curve is generated according to the real-time detection data and the personalized reference interval, so that an accurate Down's syndrome risk assessment basis is provided for clinical decisions.

The invention relates to a traditional Chinese medicine syndrome element prediction method based on collaborative filtering, belongs to the technical field of medical information processing, and solves the problem of low syndrome element prediction accuracy in the prior art. The method comprises the following steps: acquiring symptom description information of a patient and corresponding syndromes and syndrome elements to construct a training sample set; constructing a multi-task neural collaborative filtering network, and training the multi-task neural collaborative filtering network based on the training sample set to obtain a trained syndrome element prediction model; the multiple tasks comprise a syndrome element prediction task and a syndrome prediction task; and inputting the symptom description information of a to-be-predicted patient into the trained syndrome element prediction model to obtain a syndrome element prediction result of the patient. And accurate and efficient evidence element prediction is realized.

The embodiment of the present invention proposes a method and system for assisting decision-making in traditional Chinese medicine acupuncture, which relates to the technical field of traditional Chinese medicine acupuncture. The method uses a deep learning syndrome differentiation model that combines deep learning algorithms, traditional Chinese medicine syndrome differentiation theory and clinical cases to achieve high-precision syndrome type recognition, thereby improving the pertinence and accuracy of acupuncture treatment. And based on the syndrome type and symptom information of the patient, personalized acupuncture prescriptions are automatically generated to reduce the workload of clinicians and improve the efficiency and quality of acupuncture prescription formulation. The acupuncture prescription is then displayed using a three-dimensional human body model of the patient so that clinicians can intuitively view the acupuncture point combination, acupuncture point location, acupuncture depth and acupuncture direction, thereby reducing the difficulty and error of acupuncture point positioning. Through accurate acupuncture point positioning and personalized acupuncture prescriptions, the effect of acupuncture treatment and patient satisfaction are improved, thereby improving patient experience.

The invention features ALK2 antibodies and antigen binding fragments thereof (e.g., ALK2 binding fragments). The invention also features pharmaceutical compositions and methods of using the ALK2 antibodies or antigen binding fragments thereof to treat bone disease or damage, low red blood cell levels (e.g., anemia or blood loss), heterotopic ossification (e.g., heterotopic ossification resulting from fibrodysplasia ossificans progressiva), Sjogren's syndrome (e.g., dry eye associated with Sjogren's syndrome), multiple osteochondroma, diffuse intrinsic pontine glioma, posterior capsule opacification, or cardiac hypertrophy and / or cardiac fibrosis.

The invention relates to the technical field of biological medicines, and provides application of NR1D1 in treating sicca syndrome, related medicines and the like. The scheme of the invention discovers and proves that the NR1D1 gene participates in the sicca syndrome pathogenesis process, can significantly influence the function of submaxillary gland cells, and is an effective sicca syndrome immune inflammation regulation diagnosis and treatment target.

Fusion polypeptides are provided and comprise at least two ligand binding domains and a fragment crystallizable (Fc) region of immunoglobulin G (IgG). The ligand binding domains include an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-25 and / or one of the at least two ligand binding domains binds modulates B cell activity while the other modulates T cell activity. Isolated nucleic acids, vectors, and isolated cells encoding or including the fusion peptides are further provided. Pharmaceutical compositions include the fusion peptides and a pharmaceutically-acceptable vehicle, carrier, or excipient. Methods of treating Sjögren's Syndrome and / or Systemic Lupus Erythematosus are also provided and comprise administering to a subject in need thereof the fusion polypeptide including the two ligand binding domains and the Fc region of IgG.

The invention discloses application of apigenin in preparation of a product for treating sjogren syndrome, and belongs to the technical field of medicines. The apigenin is used for remarkably regulating and controlling the immune system of the body, namely enhancing the immunosuppression function of MDSCs of the body, further inhibiting activation of dendritic cells DCs, resulting in reduction of the expression level of B cell activating factors BAFF, finally achieving the purposes of inhibiting B cell differentiation and reducing immunocompetence, and relieving the symptoms of SS.

This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter- 2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of compounds.

The invention discloses application of a marker in preparation of a sicca syndrome diagnosis product, and a construction method and equipment of a diagnosis model, and relates to the technical field of sicca syndrome diagnosis. The sicca syndrome marker comprises a ratio of citrulline to arginine. The ratio of citrulline to arginine in serum has a close relationship with sicca syndrome, a diagnostic model developed based on the marker has the technical advantages of high diagnostic specificity, high sensitivity and good accuracy, and the detection method is simple, convenient and reliable and is easy to clinically popularize.

To provide a pharmaceutical composition for treating hypercortisolism in a subject of Cushing's syndrome.SOLUTION: A pharmaceutical composition contains levoketoconazole or a pharmaceutically acceptable salt thereof, and is administered to a subject in need thereof in a therapeutically effective amount. The pharmaceutical composition is administered with a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof. The subject also has type 2 diabetes and has had previous surgery or radiation to treat Cushing's syndrome. The therapeutically effective amount of the pharmaceutical composition is determined via a titration scheme including dose escalation of the pharmaceutical composition. When the subject experiences a dose limitation event, metformin or a pharmaceutically acceptable salt thereof is administered at a dose that is less than the therapeutically effective amount. The dose limitation event is reduction of a fasting blood glucose level, an abnormal renal function, a low vitamin B-12 level or any combination thereof.SELECTED DRAWING: None

The invention belongs to the technical field of life science, and particularly relates to a simulation method for liver lesion of Shushan's syndrome and application of the simulation method. The simulation method comprises the following steps: injecting an adeno-associated virus AAV8-Sbds-RNAi into an animal body, and carrying out specific SBDS gene knockout on an animal liver to obtain the Shushan syndrome hepatic lesion animal model. Liver injury after SBDS expression reduction is successfully simulated, and the model has the characteristics of simplicity in operation, short modeling period, no injury to other organs of a mouse, specificity and the like, and is beneficial to research on occurrence and development mechanisms of Shushan-Shan syndrome and research and development of therapeutic drugs.

The present disclosure relates to methods of treating Sjogren's syndrome or mixed connective tissue disease using a compound of formula (I) or a pharma- ceutically acceptable salt thereof. Also disclosed herein are compounds of formula (I) or a pharma- ceutically acceptable salt thereof for treating patients with Sjogren's syndrome or mixed connective tissue disease, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms and kits for use in the disclosed uses and methods.

The invention provides an auxiliary physical therapy device for xerostomia of sicca syndrome patients, which comprises a holding assembly and an atomization assembly arranged at the top end of the holding assembly, a liquid storage cabin is arranged above the atomization assembly, and a silica gel strip is arranged on the surface wall of the atomization assembly; wherein a protection assembly is arranged on the outer surface wall of the silica gel strip, the protection assembly is connected with the atomization assembly, the silica gel strip is located in the protection assembly, the silica gel strip is well protected when not used, the silica gel strip is prevented from being attached with bacteria, and the medical auxiliary equipment relates to the technical field of medical auxiliary equipment. A convenient and effective xerostomia physiotherapy scheme is provided for a patient, the life quality of the patient is remarkably improved, and the device has the advantages of being compact in structure, easy and convenient to operate, safe, reliable and the like.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof are provided. Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction.

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

[0366] Compounds of Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the cGAS pathway, such as autoimmune disorders including Aicardi-Goutieres Syndrome (AGS), Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Scleroderma, Sjogren's Syndrome, Inflammatory Myopathies, Hidradenitis Supperativa (HS), Parkinson's Disease, Rheumatoid Arthritis, Ulcerative Colitis and Crohn's Disease, formula (II) wherein Ra, (A), R1 and R2, are defined herein.

Disclosed herein are methods and devices for use in early detection of Richter's Syndrome. The methods include sequencing a panel of regions in cell-free DNA molecules and detecting one or more markers that are indicative of Richter's Syndrome.

Provided are compositions and methods comprising a CD40L-specific Tn3 scaffold. Also provided are methods of utilizing the same for the prevention and treatment of Sjögren's Syndrome.

The application discloses a protein zwitterionic polymer conjugate and a preparation method and application thereof. A multifunctional new medical biomaterial with mucosal adhesion, wetting, lubrication and microbial adhesion prevention is designed and synthesized, so that a new breakthrough is brought to the clinical demand of solving Sjogren's syndrome. In addition, the application has wide application prospects in the fields of oral lubrication, ophthalmic lubrication, joint repair and the like.

The invention discloses a tricyclic compound as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and uses of the compound in drugs for treating chronic kidney disease, renal or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism and Cushing's syndrome, wherein each substituent in the general formula (I) is as defined in the specification.

A compound of Formula (6): Formula (8): and Formula (10): are prepared and found useful in the treatment and / or prevention of diseases and conditions such as Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, fetal alcohol exposure, autism, schizophrenia, traumatic brain injury, stroke, addictions, Huntington's disease, Fragile X and Rett's syndrome.

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

The invention discloses an application of cGAS as a target in prevention / treatment of Leigh syndrome. The method comprises the following steps: constructing NDufs4; a cGAS DKO gene knockout mouse model is researched, and the result shows that by knocking out cGAS, the glial hyperplasia phenomenon weakening of the mouse with the Like's syndrome can be improved, and neuroinflammation is inhibited. The invention provides a new potential drug target and a treatment strategy for treating the Like's syndrome, and lays a foundation for researching and developing a new drug for treating the Like's syndrome.

The invention discloses a system for screening Reiye's syndrome based on NOD2 gene new pathogenic mutation. The invention provides a computer device. The computer device comprises a memory, a processor and a computer program stored in the memory, the processor executes the computer program to implement the following steps: receiving NOD2 gene data (cDNA sequence) of a person to be tested; the method comprises the following steps: reacting the NOD2 gene with any one of the following mutations in SEQ ID No.2 stored in a computer: c.380Cgt; t, c, 2657Cgt; t, c.328Ggt; a, c.1295Cgt is selected from the group consisting of the T, c, 1981Ggt; c, and c, 2452Agt; c) performing comparison; and according to a comparison result, outputting information about whether the to-be-detected person is or is suspected to be a patient with the Reiderson's syndrome or about the risk of suffering from the Reiderson's syndrome. The novel pathogenic gene mutation form related to the NOD2 gene of the patient with the Reidersi syndrome is found, the novel pathogenic gene mutation form can serve as a target object to be used for developing a reagent and a computer device for diagnosing or screening the Reidersi syndrome, and the novel pathogenic gene mutation form has important significance on diagnosis and screening of the Reidersi syndrome.

The invention relates to a primary sicca syndrome biomarker. The biomarker is telomere relative length. By detecting the relative length of telomeres in peripheral blood leucocytes and combining a statistical model, the early diagnosis sensitivity and specificity of the primary sicca syndrome are remarkably improved. Compared with a traditional diagnosis method, the disease risk can be predicted before clinical symptoms appear, and therefore early intervention of diseases is achieved.

Applicants disclose methods, uses, and compositions for treating patients suffering from Cushing Syndrome or Cushing Disease (collectively referred to as' CS ') without causing a significant QT interval extension (e.g., the difference of the QT interval after administration from the baseline QT interval by no more than about 10 milliseconds). The therapeutic amount of the heteroaryl ketone fused aza-naphthane compound may be from about 50 mg / day (mg / day) to up to about 500 mg / day, in embodiments, up to about 800 mg / day. The methods, uses, and compositions can shorten QT intervals, and can be used to treat QT prolongation in patients, including CS patients. The treatment may be a treatment administered orally to a fasting patient or an eating patient. The heteroaryl ketone fused aza-naphthane compounds can be administered with meals. The heteroaryl ketone fused aza-naphthane compound may be reracolan, which is (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl) sulfonyl)-4, 4a, 5, 6, 7, 8-hexahydro-1H-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4-(trifluoromethyl) pyridin-2-yl) methanone having the following structure (I) # imgabs 0 #